Physician profile
Tamara Bailey
NPI 1184122327
$5,292.83
in general payments reported to CMS, 2019-2025
43 companies · $965 in 2025
The $965 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,293 · 2022: $1,059 · 2023: $937 · 2024: $1,038 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,940.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $554.83 | 2021-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Lilly USA, LLC | $446.68 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Abbvie INC. | $409.48 | 2021-2025 | |
| Novo Nordisk INC | $343.55 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $329.56 | 2021-2025 | Rexulti |
| Abbott Laboratories | $258.57 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $258.40 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $223.20 | 2021-2025 | Trintellix |
| Glaxosmithkline, LLC. | $221.92 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $212.67 | 2021-2024 | Prolia, Evenity, Otezla |
| Janssen Pharmaceuticals, INC | $174.30 | 2021-2022 | |
| Exact Sciences Corporation | $168.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| W. L. Gore & Associates, INC. | $145.66 | 2024 | Gore Cardioform Septal Occluder |
| Sumitomo Pharma America, INC. | $112.28 | 2023-2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $111.62 | 2022-2024 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.